Dashboard
Manage Tickers

BOLD Boundless Bio, Inc.

Nasdaq boundlessbio.com


$ 1.31 $ 0.02 (1.54 %)    

Tuesday, 14-Oct-2025 15:59:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 598.11 $ -4.01 (-0.67 %)
DIA $ 462.92 $ 2.03 (0.44 %)
SPY $ 662.17 $ -0.81 (-0.12 %)
TLT $ 90.68 $ 0.29 (0.32 %)
GLD $ 381.35 $ 2.70 (0.71 %)
$ 1.32
$ 1.27
$ 1.30 x 130
$ 1.45 x 100
$ 1.24 - $ 1.44
$ 1.00 - $ 3.75
391,824
na
29.55M
$ 1.98
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

boundless-bio-to-present-preclinical-data-on-bbi-825-and-bbi-355-combo-targeting-oncogene-amplified-cancers-at-aacr-nci-eortc-2025
Boundless Bio To Present Preclinical Data ...
10/13/2025 20:10:51

Boundless Bio, (NASDAQ:BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver tr...

hc-wainwright--co-maintains-buy-on-boundless-bio-lowers-price-target-to-4
HC Wainwright & Co. Maintains Buy on Bound...
08/11/2025 10:43:08

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Boundless Bio (NASDAQ:BOLD) with a Buy and lowers the price tar...

boundless-bio-q2-eps-070-beats-071-estimate
Boundless Bio Q2 EPS $(0.70) Beats $(0.71)...
08/05/2025 11:25:33

hc-wainwright--co-initiates-coverage-on-boundless-bio-with-buy-rating-announces-price-target-of-5
HC Wainwright & Co. Initiates Coverage On ...
06/02/2025 10:45:15

HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Buy rating and anno...

leerink-partners-downgrades-boundless-bio-to-market-perform-lowers-price-target-to-3
Leerink Partners Downgrades Boundless Bio ...
05/28/2025 15:53:30

Leerink Partners analyst Michael Cherny downgrades Boundless Bio (NASDAQ:BOLD) from Outperform to Market Perform and lowers ...

boundless-bio-announces-portfolio-prioritization-and-runway-extension-prioritizes-bbi-355bbi-825-combination-and-bbi-940-discontinues-current-arms-of-bbi-355-in-potentiate-trial-to-evaluate-bbi-355bbi-825-combination-in-2025-reduces-workforce-by-one-third
Boundless Bio Announces Portfolio Prioriti...
05/23/2025 20:05:27

boundless-bio-q1-eps-071-beats-073-estimate
Boundless Bio Q1 EPS $(0.71) Beats $(0.73)...
05/09/2025 11:19:39

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.73)...

boundless-bio-files-for-mixed-shelf-of-up-to-400m
Boundless Bio Files For Mixed Shelf Of Up ...
04/01/2025 20:04:03

-SEC Filing

boundless-bio-q4-2024-gaap-eps-074-beats-077-estimate
Boundless Bio Q4 2024 GAAP EPS $(0.74) Bea...
03/27/2025 11:08:01

guggenheim-downgrades-boundless-bio-to-neutral
Guggenheim Downgrades Boundless Bio to Neu...
12/13/2024 13:26:45

Guggenheim analyst Yige Guo downgrades Boundless Bio (NASDAQ:BOLD) from Buy to Neutral.

boundless-bio-announces-pipeline-and-leadership-updates-company-elects-not-to-advance-bbi-825-into-part-2-portion-of-starmap-clinical-trial-operating-runway-extended-into-2027
Boundless Bio Announces Pipeline And Leade...
12/12/2024 21:06:11

Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trialThird ecDTx program advancing, with plans fo...

boundless-bio-q3-2024-gaap-eps-074-beats-082-estimate
Boundless Bio Q3 2024 GAAP EPS $(0.74) Bea...
11/07/2024 21:56:15

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.82)...

boundless-bio-announces-jami-rubin-steps-down-as-cfo-co-does-not-plan-to-hire-a-successor-at-this-time-says-david-hinkle-senior-vice-president-finance-and-controller-will-maintain-responsibility-for-finance-operations
Boundless Bio Announces Jami Rubin Steps D...
10/14/2024 12:09:59

leerink-partners-initiates-coverage-on-boundless-bio-with-outperform-rating-announces-price-target-of-25
Leerink Partners Initiates Coverage On Bou...
04/22/2024 19:11:31

Leerink Partners analyst Michael Cherny initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Outperform rating and annou...

guggenheim-initiates-coverage-on-boundless-bio-with-buy-rating-announces-price-target-of-24
Guggenheim Initiates Coverage On Boundless...
04/22/2024 11:18:20

Guggenheim analyst Yige Guo initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Buy rating and announces Price Target o...

piper-sandler-initiates-coverage-on-boundless-bio-with-overweight-rating-announces-price-target-of-20
Piper Sandler Initiates Coverage On Boundl...
04/22/2024 09:20:36

Piper Sandler analyst Joseph Catanzaro initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Overweight rating and announ...

boundless-bio-doses-first-patient-in-phase-12-clinical-trial-of-bbi-825-in-cancer-patients-with-resistance-gene-amplifications
Boundless Bio Doses First Patient In Phase...
04/11/2024 12:07:17

boundless-bio-presents-preclinical-and-clinical-pharmacodynamic-data-on-lead-ecdna-directed-therapy-bbi-355-at-aacr-annual-meeting-2024
Boundless Bio Presents Preclinical And Cli...
04/08/2024 12:20:10

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase ...

trading-halt-halt-status-updated-at-101000-am-et-quotation-resumption-ipo-security---released-for-quotation
Trading Halt: Halt status updated at 10:10...
03/28/2024 14:10:06

reported-earlier-boundless-bio-prices-initial-public-offering-of-625m-common-shares-at-16share
Reported Earlier, Boundless Bio Prices Ini...
03/28/2024 06:57:34

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION